{"name":"Chinook Therapeutics","slug":"chinook","ticker":"KDNY","exchange":"NASDAQ","domain":"chinooktx.com","description":"","hq":"Seattle, WA","founded":0,"employees":"","ceo":"","sector":"Kidney Disease / IgAN","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"BION-1301","genericName":"BION-1301","slug":"bion-1301","indication":"Hepatocellular carcinoma (HCC), FGFR4-positive","status":"phase_3"}]}],"pipeline":[{"name":"BION-1301","genericName":"BION-1301","slug":"bion-1301","phase":"phase_3","mechanism":"BION-1301 is a monoclonal antibody that targets and inhibits FGFR4 (fibroblast growth factor receptor 4) to reduce hepatocellular carcinoma cell growth and survival.","indications":["Hepatocellular carcinoma (HCC), FGFR4-positive"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}